Transparency and reporting characteristics of COVID-19 randomized controlled trials

202225 citationsJournal Articlegold Open Access

Authors

Philipp Kapp · Centre de Recherche Épidémiologie et Statistique

Laura Esmail · Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

Lina Ghosn · Assistance Publique – Hôpitaux de Paris

Philippe Ravaud · Centre de Recherche Épidémiologie et Statistique

Isabelle Boutron · Centre de Recherche Épidémiologie et Statistique

Abstract

Transparency, completeness, and consistency of reporting of COVID-19 clinical trials were insufficient both in preprints and peer-reviewed publications. A comparison of paired reports published in preprint and peer-reviewed publication did not indicate major improvement.

Topics & Keywords

Academic Publishing and Open Access Meta-analysis and systematic reviews Ethics in Clinical Research

Publication Details

Published in: BMC Medicine

Volume 20, Issue 1, pp. 363-363

DOI: 10.1186/s12916-022-02567-y

Field-Weighted Citation Impact: 11.11

Command Palette

Transparency and reporting characteristics of COVID-19 randomized controlled trials

Authors

Abstract

Topics & Keywords

Publication Details